Total Holdings
46
Portfolio diversification across 46 positions
SURI
(NYSEARCA)Simplify Propel Opportunities ETF
$15.85-- (--)
Loading... - Market loading
SURI ETF Holdings: Simplify Propel Opportunities ETF
Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Asset Allocation ETF. Analyze fund diversification and concentration.
Assets Under Management
$76.48M
Total fund assets
Expense Ratio
2.57%
Annual management fee
Fund Issuer
Simplify
NYSEARCA
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 36 Holdings by Portfolio Weight
View ticker symbols, company names, asset types, and allocation percentages for each position
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Plains GP Holdings, L.P. | Stock | 43.34% |
| 2 |  | Achieve Life Sciences, Inc | Stock | 6.70% |
| 3 |  | Phathom Pharmaceuticals, Inc | Stock | 5.48% |
| 4 |  | Delcath Systems, Inc. | Stock | 3.56% |
| 5 |  | Milestone Pharmaceuticals Inc | Stock | 3.42% |
| 6 |  | Abeona Therapeutics Inc. | Stock | 3.41% |
| 7 |  | Celldex Therapeutics, Inc. | Stock | 3.03% |
| 8 |  | Oculis Holding AG Ordinary shares | Stock | 2.84% |
| 9 |  | Viridian Therapeutics Inc | Stock | 2.76% |
| 10 |  | LeonaBio, Inc. | Stock | 2.40% |
| 11 |  | Corcept Therapeutics Incorporated | Stock | 2.27% |
| 12 |  | Kyverna Therapeutics, Inc. | Stock | 2.17% |
| 13 |  | Inventiva Sa | Stock | 2.06% |
| 14 |  | Cash | Stock | 1.67% |
| 15 |  | COMPASS Pathways plc | Stock | 1.62% |
| 16 |  | 4D Molecular Therapeutics Inc | Stock | 1.45% |
| 17 |  | Aquestive Therapeutics, Inc. | Stock | 1.37% |
| 18 |  | Vor Biopharma Inc. | Stock | 1.37% |
| 19 |  | Orchestra BioMed Holdings, Inc. | Stock | 1.33% |
| 20 |  | Zevra Therapeutics, Inc. | Stock | 1.28% |
| 21 | T TELSAT.5.625 12.06.26 144A | TELSAT 5.625 12/06/26 144A Corp | Stock | 1.18% |
| 22 |  | Trevi Therapeutics, Inc. | Stock | 1.11% |
| 23 |  | Ocular Therapeutix, Inc. | Stock | 1.08% |
| 24 |  | Upstream Bio, Inc. | Stock | 1.05% |
| 25 |  | Nuvation Bio Inc | Stock | 1.05% |
| 26 |  | SAB Biotherapeutics, Inc. | Stock | 1.03% |
| 27 |  | EyePoint, Inc. | Stock | 1.02% |
| 28 |  | KLRS | Stock | 0.96% |
| 29 |  | Aardvark Therapeutics, Inc. Common Stock | Stock | 0.92% |
| 30 |  | Coherus BioSciences, Inc | Stock | 0.81% |
| 31 |  | Palisade Bio Inc | Stock | 0.79% |
| 32 |  | LENZ Therapeutics Inc | Stock | 0.76% |
| 33 | K KMPH | KemPharm Inc | Stock | 0.44% |
| 34 |  | Nektar Therapeutics | Stock | 0.31% |
| 35 |  | Theravance Biopharma Inc | Stock | 0.30% |
| 36 | E EPA:ALSEN | Sensorion SA | Stock | 0.12% |
Frequently Asked Questions About Simplify Propel Opportunities ETF Holdings
What are the top holdings in SURI?
Simplify Propel Opportunities ETF (SURI) holds 46 securities. View the complete list of top holdings sorted by portfolio weight, showing each security's ticker symbol, company name, asset type, and allocation percentage.
How concentrated is SURI's portfolio?
Portfolio concentration is measured by the weight of top holdings. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly. Review SURI's holdings table to analyze concentration risk.
What is SURI's sector allocation?
The Sector Allocation chart shows how SURI distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does SURI invest in?
SURI's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is SURI ETF?
SURI's diversification can be assessed by reviewing its 46 holdings, sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.